Page 270 - Assurance of Sterility for Sensitive Combination Products and Materials
P. 270

248   Index


          Hoods, caps, and shoe covers, 154  L
          Hospital Infection Control Practices   Labeling products as sterile
               Advisory committee (HICPAC),   regulatory authorities, communication
               148–149                           with, 222–223
          Hospital infection rates vs. medical device,   SAL, 222
               204f                         Leachable, 104
          Humanitarian device exemption (HDE)   Leakage, 97
               applications, 223            Line of sight (LOS) approach, 44–46
          Humidity, 81                      Lower confidence bound (LCB), 184
          Hydrogen peroxide, 160
          Hydrogen peroxide/ozone, 161      M
          Hypochlorite-based product (bleach), 139  Market authorization as medicinal product,
                                                 226–227
          I                                 Material qualifications, chemical, and
          Immediate use steam sterilization, 159–160  biological compatibility, 103
          Immuno-compromised status, 202    Medical device
          Indirect person to person spread of   associated infections, 146
               microbes, 144                 vs. pharmaceutical packaging, 83–87
          Industrial single-use devices, 146  Medicinal products
          Industry sectors vs. real-world infection   EMA guidance, 222
               rates                         evaluation, terminal sterilization,
            bioburden control, in manufacturing   235–236
               environment, 202–203          market authorization, EU submission
            hospital infection rates vs. medical device,   process, 226–227
               204f                         Medtronic Infuse Bone Graft/LT-CAGE
            infection probabilities estimation, 196–201  lumbar tapered fusion device, 18, 19f
            OC curve, 189f                  Methicillin resistant Staphylococcus aureus
            patient’s immuno-compromised status,   (MRSA), 141
               202                          Microbial barrier
            PNSU* and upper confidence bounds,   properties, 103
               191f                          test methods, 99–100
            representative risk graph, 168f  Microbial contamination case study, 64–66
            sterilization validation methodology, 203  Microorganisms, sources, 141–145
          Infection probabilities estimation, 196–201  Microspheres, 7–8
            P1, 197                         Moist sterilization history, 26–27
            P2, 197–200                     Multidrug-resistant organisms (MDROs), 141
            P3, 200
            P4, 200–201                     N
          International Standards (ISO), 222  Non-device-associated infections, 145–146
            guidance, 233–234               Non-device-associated infections, 145–146
            ISO 11607, 103                  Nonparametric analysis, 176–177
            ISO 14971                       Nonsurgical setting attire, 151–152
              core concept, 169             Normothermia, postoperative, 154
              risk management process, 168t
            13408 series, 234–235           O
          Investigational device exemption (IDE)   Overkill method. See also BI approach
               applications, 223             point estimates and confidence bounds,
          Isolators/barrier isolators, 59–60     191–194
   265   266   267   268   269   270   271   272   273   274   275